Every AI-powered diagnostic tool a hospital or clinic purchases has, in principle, passed through FDA review — but the specific pathway that review takes, and what it actually verifies, is less well understood outside regulatory circles than the simple fact of "FDA clearance" suggests.
The 510(k) Pathway Dominates AI Clearances
The overwhelming majority of AI-enabled medical devices reach market through the 510(k) pathway, which requires the manufacturer to demonstrate the new device is "substantially equivalent" to an already-cleared predicate device, rather than proving safety and efficacy from scratch through the more rigorous premarket approval (PMA) process required for novel high-risk devices. This pathway was designed decades before adaptive AI software existed, and its core logic — comparing a new device to an existing one — sits somewhat awkwardly against software whose core value proposition is often that it works differently than anything that came before.
The "Locked" vs. "Adaptive" Algorithm Distinction
A critical regulatory concept is the distinction between locked and adaptive algorithms. A locked algorithm's decision logic is fixed at the time of clearance — it doesn't change based on new data encountered in clinical use, and any update requires a new or supplemental FDA submission. Nearly all currently cleared AI medical devices use locked algorithms for exactly this reason: it's the clearer regulatory path.
True adaptive algorithms — models that continuously learn and update their decision logic from real-world data without a new submission for every change — remain largely outside current FDA clearance in the U.S., though the agency has published a framework (the Predetermined Change Control Plan, or PCCP) allowing manufacturers to pre-specify the bounds within which a model may adapt without requiring resubmission for each change. This represents the FDA's attempt to build a regulatory pathway suited to genuinely adaptive software, and its adoption is expected to grow.
What Clearance Actually Verifies
FDA clearance confirms a device met its stated performance benchmarks on the validation dataset used in the submission — it does not independently verify the device will perform identically across every clinical setting, patient population, or piece of hardware it's eventually deployed on. This is why the FDA has increasingly emphasized post-market surveillance requirements, and why sophisticated health systems conduct their own local validation studies before fully trusting a newly deployed AI tool, particularly for high-stakes diagnostic categories.
De Novo and Breakthrough Device Pathways
For genuinely novel AI devices without an existing predicate, the De Novo pathway offers an alternative route to market that still falls short of full PMA rigor but requires the manufacturer to establish special controls specific to the new device category — these special controls then become the benchmark against which future similar devices seek 510(k) clearance. The FDA's Breakthrough Devices Program can additionally expedite review timelines for devices addressing serious conditions with no adequate existing alternative, a designation a growing number of AI diagnostic tools have received.
What This Means for Purchasing Decisions
For healthcare facilities evaluating AI-enabled devices, understanding the clearance pathway matters practically: a 510(k)-cleared device's performance claims should be read against the specific predicate and validation dataset cited in its clearance summary (publicly searchable in the FDA's database), not assumed to generalize universally. Facilities can review a product's specific FDA clearance status alongside its clinical evidence base as part of standard procurement due diligence.
Conclusion
FDA clearance is a meaningful regulatory signal, but it's a narrower one than "FDA approved" branding sometimes implies to clinicians and patients. Understanding what pathway a device took, what predicate it was compared against, and whether its algorithm is locked or adaptive gives purchasers a much clearer picture of what that clearance actually guarantees.
